

Validation of an industrial process to manufacture isosorbide bis(methyl carbonate) at pilot level

Deliverable D1.5

Project Management Plan (I)

Lead Beneficiary TECNALIA Delivery Date 29/10/2018 Dissemination Level Public Status Approved Version 1 Keywords WorkBreakdown Structure, Gantt Chart



This project has received funding from the Bio Based Industries Joint Undertaking (JU) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 790440. The JU receives support from the European Union's Horizon 2020 research and innovation programme and the Bio Based Industries Consortium.



Disclaimer

This Deliverable reflects only the author's views and the BBI-JU is not responsible for any use that may be made of the information contained therein

Document Information

Grant Agreement Number	790440
Project Acronym	VIPRISCAR
Work Package	WP 1
Related Task(s)	T1.1
Deliverable	D1.5
Title	Project Management Plan (I)
Responsible Author	Soraya Prieto (Tecnalia)
Contributor(s)	Erasmo Cadena (VERTECH), Yaying Chen (EXERGY), Daniela Klein (JOWAT), Hartmut Henneken (JOWAT), Ruben Seoane (GAIKER), Hector Linuesa (Leitat), Stefaan De Wildeman (B4P), Elena Benedetti (AEP)
File Name	VIPRISCAR_D1.5_Project Management Plan(I)_v1_20181029.docx

Revision History

Revision	Date	Description	Reviewer
1	29-10-2018	First version	Hector Linuesa (LEITAT)





EXECUTIVE SUMMARY

The main purpose of this deliverable is to document the Work Breakdown Structure (WBS) and the related elements that support the project's schedule:

Project task durations, dependencies and responsibilities,

Project milestones,

- Project deliverables,
- Project management mechanisms, and
- Gantt Chart.

The VIPRISCAR project work plan is results-based, with each Work Package (WP) mapping to an objective to produce new bioproducts form IBMC. The project is structured to ensure balanced work load and unambiguous responsibility for tasks and deliverables, with each deliverable responsibility of the task leader unless otherwise explicit in the WP description.

A Gantt Chart is annexed to this document to better understand the schedule of the different Work Packages and their components. The inter-relationships among the different project tasks and components is presented both graphically and in WP tables. The project schedule will be managed through success criteria, milestones and periodic control mechanisms.

The actual schedule performance will be compared to planned performance to implement corrective action when actual performance deviates from planned or required performance.

The Project Management Plan will be updated four times during the project execution (at Months 3, 12, 24 and 36).

Furthermore, Work Package and Tasks Leaders will be responsible for reporting on their activities at every Project Steering Committee meeting (every 6 months) to allow project progress to be tracked seamlessly. The actual Gantt Chart will then reflect progress achieved and agreement of the revised schedule, if necessary.

The intended audience of the Project Management Plan (PMP) is all project stakeholders including the BBI-JU, senior leadership and the project team.





TABLE OF CONTENTS

EXECUTIVE SUMMARY	3
TABLE OF CONTENTS	4
LIST OF FIGURES	5
LIST OF TABLES	6
ABBREVIATIONS AND ACRONYMS	7
1. INTRODUCTION	8
2. WORK BREAKDOWN STRUCTURE AND SCHEDULE	9
2.1 WORK PLAN STRUCTURE	9
2.2 WP1: Management and scientific coordination	10
2.3 WP2: IBMC process development and validation at lab scale	11
2.4 WP3: IBMC process validation at pilot plant	12
2.5 WP4: Coating application proof-of-principle	13
2.6 WP5: Adhesives application proof of principle	15
2.7 WP6: Bifunctional catheters application proof of principle	16
2.8 WP7: LCA, REACH and cost analysis	17
2.9 WP8: Exploitation, Dissemination and Communication	19
2.10 WP9: Ethics Requirement	20
3. GRAPHICAL PRESENTATION OF TASKS INTERDEPENDENCIES	21
4. SCHEDULE MANAGEMENT	22
4.1 PROJECT SUCCESS CRITERIA	22
4.2 MILESTONES	24
4.3 CONTROL MECHANISMS	25
ANNEX I: VIPRISCAR GANTT CHART	





LIST OF FIGURES





LIST OF TABLES

TABLE 2.1: LIST OF WORK PACKAGES	9
TABLE 2.2: WBS FOR WP1	
TABLE 2.3: WBS FOR WP2	
TABLE 2.4: WBS FOR WP3	
TABLE 2.5: WBS FOR WP4	
TABLE 2.6: WBS FOR WP5	
TABLE 2.7: WBS FOR WP6	
TABLE 2.8: WBS FOR WP7	
TABLE 2.9: WBS FOR WP8	
TABLE 2.10: WBS FOR WP9	
TABLE 4.1: PROJECT SUCCESS CRITERIA	
TABLE 4.2: PROJECT MILESTONES	24





ABBREVIATIONS AND ACRONYMS

- GA Grant Agreement
- PM Person-months
- PMP Project Management Plan
- WBS Work Breakdown Structure
- WP Work Package





1. INTRODUCTION

The Grant Agreement (GA) provides an in-depth description of the different Work Packages and components. However, the information is presented in such a way that hampers the appropriate management during project execution.

The Project Management Plan (PMP) is a formal document used to guide both project execution and project control. By showing the major deliverables, milestones, activities and responsibilities on the project, it is also a statement of how and when a project's objectives are to be achieved.

The main purpose of this deliverable is therefore to document the Work Breakdown Structure (WBS) and the related elements that support the project's schedule:

- Project task durations, dependencies and responsibilities,
- Project milestones,
- Project deliverables,
- Project management mechanisms, and
- Gantt Chart.

The intended audience of the PMP is all project stakeholders including the BBI-JU, senior leadership and the project team.

This deliverable, directly linked to task T1.2, is structured in the following chapters:

- **Chapter 1**: Introduction. Main purpose, intended audience and structure of the document.
- **Chapter 2**: Work breakdown structure and schedule. Work plan structure and individual Work Package description.
- **Chapter 3**: Graphical presentation of tasks interdependencies. Inter-relationships among the different project tasks and components
- **Chapter 4**: Schedule management. Success criteria, milestones and periodic control mechanisms.
- Annex I: VIPRISCAR Project Gantt Chart.





2. WORK BREAKDOWN STRUCTURE AND SCHEDULE

2.1 WORK PLAN STRUCTURE

The VIPRISCAR project work plan is results-based, with each Work Package mapping to an objective to produce new bioproducts form IBMC, as presented in sections 1.3.1, 1.3.3 and 1.3.4 of the Grant Agreement. In addition, many issues are cutting across each Work Package, risk, costs and data collection. WP8 is in charge of providing consistent methodology, data collection protocol and integration of this information.

The project is structured to ensure balanced work load and unambiguous responsibility for tasks and deliverables, with each deliverable responsibility of the task leader unless otherwise explicit in the WP description.

Table 1 summarises the main project components. In the following sections, details of the individual Work Packages are given including interdependencies among tasks and deliverables. A Gantt Chart is annexed to this document to better understand the schedule of the different Work Packages and their components.

WP	Title	Lead	PM	Start	End				
WP1	Management and scientific coordination	TECNALIA	28	1	36				
WP2 IBMC process development and validation at lab scale		TECNALIA	56	1	12				
WP3	IBMC process validation at pilot plant	B4P	45	9	24				
WP4	Coating application proof-of-principle	AEP	64	13	36				
WP5	Adhesives application proof of principle	JOWAT	79.4	13	36				
WP6	Bifunctional catheters application proof of principle	CIKAUTXO	57	13	36				
WP7	LCA, REACH and cost analysis	VERTECH	64	6	36				
WP8	Exploitation, Dissemination and Communication	VERTECH	55	1	36				
WP9	Ethics Requirement	TECNALIA	N/A	1	36				
			448.4						

TABLE 2.1: LIST OF WORK PACKAGES





2.2 WP1: Management and scientific coordination

	TABLE 2.2: WBS FOR WP1										
Participant number	1	2	3	4	5	6	7	8	9		
Short name of participant	TECNALIA	JOWAT	CIKAUTXO	B4P	AEP	VERTECH	EXERGY	GAIKER	LEITAT		

ID	Description	Lead	Participants	Depends	Start	Due
WP1	Management and scientific coordination	1	2, 3, 4, 5, 6, 7, 8, 9	-	1	36
T1.1	Project coordination and quality assurance	1	2, 3, 4, 5, 6, 7, 8, 9	-	1	36
T1.2	Communication, reporting and monitoring	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	1	36

			Partner nº								
	Project	1	2	3	4	5	6	7	8	9	т
	T1.1	10	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	14
	T1.2	10	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	14
	Total	20	1	1	1	1	1	1	1	1	28
Σ											
Planned Effort (PM)	RP1	1	2	3	4	5	6	7	8	9	т
ffor	T1.1	5	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	7
вd Е	T1.2	5	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	7
nne	Total	10	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	14
Pla											
	RP2	1	2	3	4	5	6	7	8	9	т
	T1.1	5	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	7
	T1.2	5	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	7
	Total	10	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	14

ID	Description	Lead	Participants	Depends	Start	Due
D1.1	Quality Assurance Plan (I)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.1	-	3
D1.2	Quality Assurance Plan (II)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.1	-	12
D1.3	Quality Assurance Plan (III)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.1		24
D1.4	Quality Assurance Plan (IV)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.1		36
D1.5	Project Management Plan (I)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.2		3
D1.6	Project Management Plan (II)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.2		12
D1.7	Project Management Plan (III)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.2		24
D1.8	Project Management Plan (IV)	1	2, 3, 4, 5, 6, 7, 8, 9	T1.2		36





2.3 WP2: IBMC process development and validation at lab scale

TABLE 2.3: WBS FOR WP2							
Participant number	1	4	7				
Short name of participant	TECNALIA	B4P	EXERGY				

ID	Description	Lead	Participants	Depends	Start	Due
WP2	IBMC Process development and validation at lab scale	1	4, 7	-	1	12
T2.1	Reaction improvement	1	4		1	12
T2.2	Separation and purification procedure	1	4	T2.1	4	12
T2.3	Pre-up-scaling	1	4	T2.1, T2.2	10	12
T2.4	Process design and integration	7	1, 4	T2.1, T2.2, T2.3	6	12
T2.5	Process simulation and preliminary up- scaling	7	1, 4	T2.4	8	12

	_					Partn	er nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T2.1	13	0	0	1	0	0	0	0	0	14
	T2.2	13	0	0	1	0	0	0	0	0	14
	T2.3	10	0	0	1	0	0	0	0	0	11
	T2.4	2	0	0	0.6	0	0	6	0	0	8.6
	T2.5	2	0	0	0.4	0	0	6	0	0	8.4
	Total	40	0	0	4	0	0	12	0	0	56
-	RP1	1	2	3	4	5	6	7	8	9	Т
Planned Effort (PM)	T2.1	13	0	0	1	0	0	0	0	0	14
	T2.2	13	0	0	1	0	0	0	0	0	14
A Eff	T2.3	10	0	0	1	0	0	0	0	0	11
nec	T2.4	2	0	0	0.6	0	0	6	0	0	8.6
Plar	T2.5	2	0	0	0.4	0	0	6	0	0	8.4
	Total	40	0	0	4	0	0	12	0	0	56
	RP2	1	2	3	4	5	6	7	8	9	Т
	T2.1	0	0	0	0	0	0	0	0	0	0
	T2.2	0	0	0	0	0	0	0	0	0	0
	T2.3	0	0	0	0	0	0	0	0	0	0
	T2.4	0	0	0	0	0	0	0	0	0	0
	T2.5	0	0	0	0	0	0	0	0	0	0
	Total	0	0	0	0	0	0	0	0	0	0





ID	Description	Lead	Participants	Depends	Start	Due
D2.1	Mid report on IBMC process	1	4	T2.1	-	3
	development					
D2.2	Final report on IBMC process	1	4	T2.3	-	12
	development. Lab Technology Manual					
D2.3	Process simulation and preliminary up-	7	1, 4	T2.5		24
	scaling report					

ID	Description	Lead	Participants	Depends	Start	Due
MS1	Production of 1 kg of IBMC	1	-	-	-	12

2.4 WP3: IBMC process validation at pilot plant

TABLE 2.4: WBS FOR WP3									
Participant number	1	4	7						
Short name of participant	TECNALIA	4t8	EXERGY						

ID	Description	Lead	Participants	Depends	Start	Due
WP3	IBMC Process validation at pilot plant	4	1, 7	-	9	24
T3.1	Intermediate scaling-up	4	1	T2.3	9	12
T3.2	Pilot plant design	4	1, 7	T2.5, T3.1	9	12
T3.3	Pilot plant starting	4	1	T2.5, T3.2	11	12
T3.4	Pilot plant operation	4	1, 7	Т3.3	13	24
T3.5	Plant up-scaling simulation to industrial scale	7	4	T2.5, T3.4	11	24

						Partn	ler nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T3.1	3	0	0	5	0	0	0	0	0	8
	T3.2	3	0	0	5	0	0	4	0	0	12
~	Т3.3	3	0	0	5	0	0	0	0	0	8
Effort (PM)	T3.4	1	0	0	5	0	0	2	0	0	8
to	T3.5	0	0	0	2	0	0	7	0	0	9
Eff	Total	10	0	0	22	0	0	13	0	0	45
ned											
Planned	RP1	1	2	3	4	5	6	7	8	9	т
	T3.1	3	0	0	5	0	0	0	0	0	8
	T3.2	3	0	0	5	0	0	4	0	0	12
	T3.3	3	0	0	5	0	0	0	0	0	8
	T3.4	0.5	0	0	2.5	0	0	1	0	0	4



D1.5 Project Management Plan (I)



T3.5	0	0	0	1.14	0	0	4	0	0	5.14
Total	9.5	0.0	0.0	18.64	0.0	0.0	9	0	0	37.14
RP2	1	2	3	4	5	6	7	8	9	т
T3.1	0	0	0	0	0	0	0	0	0	0
T3.2	0	0	0	0	0	0	0	0	0	0
T3.3	0	0	0	0	0	0	0	0	0	0
T3.4	0.5	0	0	2.5	0	0	1	0	0	4
T3.5	0	0	0	0.86	0	0	3	0	0	3.86
Total	0.5	0	0	3.36	0	0	4	0	0	7.86

ID	Description	Lead	Participants	Depends	Start	Due
D3.1	Mid report on IBMC pilot process validation, including adaptation/investments	4	1	T3.4	-	16
D3.2	Final protocol report on optimal IBMC pilot process	4	1, 7	T3.4	-	24
D3.3	Report on plant up-scaling simulation to industrial scale	7	4	T3.5		24

ID	Description	Lead	Participants	Depends	Start	Due
MS2	100 kg of IBMC produced	4	-	-	-	24

2.5 WP4: Coating application proof-of-principle

TABLE 2.5: WBS FOR WP4									
Participant number	1	5	8						
Short name of participant	TECNALIA	AEP	GAIKER						

ID	Description	Lead	Participants	Depends	Start	Due
WP4	Coating application proof-of-principle	5	1, 8	-	13	36
T4.1	Waterborne polyurethane dispersions (PUDs) for coatings	8	1, 5	T3.4, T4.3	13	27
T4.2	IBMC based NIPUs for coatings	5	1, 8	T3.4, T4.3	13	27
T4.3	Coating formulation and testing of properties	5	8	T4.1, T4.2	19	36





						Partn	er nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T4.1	0.5	0	0	0	6	0	0	22	0	28.5
	T4.2	0.5	0	0	0	6	0	0	8	0	14.5
	T4.3	0	0	0	0	6	0	0	15	0	21
	Total	1	0	0	0	18	0	0	45	0	64
_										-	_
Planned Effort (PM)	RP1	1	2	3	4	5	6	7	8	9	т
	T4.1	0.29	0	0	0	3.43	0	0	12	0	15.71
l Eff	T4.2	0.29	0	0	0	3.43	0	0	5	0	8.71
ned	T4.3	0	0	0	0	0	0	0	0	0	0
Plan	Total	0.57	0	0	0	6.86	0	0	17	0	24.43
_											
	RP2	1	2	3	4	5	6	7	8	9	т
	T4.1	0.21	0	0	0	2.57	0	0	10	0	12.79
	T4.2	0.21	0	0	0	2.57	0	0	3	0	5.79
	T4.3	0	0	0	0	6	0	0	15	0	21
	Total	0.43	0	0	0	11.14	0	0	28	0	39.57

ID	Description	Lead	Participants	Depends	Start	Due
D4.1	Waterborne polyurethane dispersions (PUDs) from hydroxylfunctional IBMC (oligo)carbonates	8	1, 5	T4.1	-	27
D4.2	IBMC-derived NIPUS with amino terminal groups	5	1, 8	T4.2	-	27
D4.3	IBMC based coatings from PUDs and NIPUS	5	8	T4.3		36

ID	Description	Lead	Participants	Depends	Start	Due
MS3	At least 1 IBMC-based polymer shows preliminary suitable behaviour for one	1	-	-	-	27
	of the applications					





2.6 WP5: Adhesives application proof of principle

TABLE	2.6:	WBS	FOR	WP5
IADLL	2.0.	** 05	100	VVI J

Participant number	1	2	9
Short name of participant	TECNALIA	TAWOL	LEITAT

ID	Description	Lead	Participants	Depends	Start	Due
WP5	Adhesives application proof-of-principle	2	1, 9	-	13	36
T5.1	Adhesives based on IBMC and commercial polyester/polyether polyols.	9	2	T3.4, T5.3	13	27
T5.2	NIPUs-based adhesives	1	2	T3.4, T5.3	13	27
T5.3	Adhesives formulation and testing of properties	2	1, 9	T5.1, T5.2	24	36

						Partn	er nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T5.1	0	1.7	0	0	0	0	0	0	22	23.7
	T5.2	15.5	1.7	0	0	0	0	0	0	0	17.2
	T5.3	15.5	5	0	0	0	0	0	0	18	38.5
	Total	31	8.4	0	0	0	0	0	0	40	79.4
Planned Effort (PM)	RP1	1	2	3	4	5	6	7	8	9	т
ort (T5.1	0	0.97	0	0	0	0	0	0	12.57	13.54
l Eff	T5.2	8.86	0.97	0	0	0	0	0	0	0	9.83
ned	T5.3	0	0	0	0	0	0	0	0	0	0
Plan	Total	8.86	1.94	0	0	0	0	0	0	12.57	23.37
_											
	RP2	1	2	3	4	5	6	7	8	9	т
	T5.1	0	0.73	0	0	0	0	0	0	9.43	10.16
	T5.2	6.64	0.73	0	0	0	0	0	0	0	7.37
	T5.3	15.5	5	0	0	0	0	0	0	18	38.5
	Total	22.14	6.46	0	0	0	0	0	0	27.43	56.03

ID	Description	Lead	Participants	Depends	Start	Due
D5.1	Selection of raw materials and	1	2, 9	T5.1, T5.2	-	15
	definition of adhesives applications					
D5.2	Polycarbonate polyols from IBMC at	9	2	T5.1	-	20
	lab scale (50g). Report on the					
	preparation and characterisation of					
	IBMC based adhesive prepolymers and					





	characterization thereof					
D5.3	Synthesis of IBMC-based NIPUs. First approaches	1	2	T5.2	-	20
D5.4	Raw materials (2 kg) for adhesive formulation provided by LEITAT to JOWAT	9	2	T5.1	-	27
D5.5	Synthesis of IBMC-based NIPUs. Final formulation	1	2	T5.2	-	27
D5.6	Adhesive formulations and characterization	2	1, 9	T5.3	-	36

ID	Description	Lead	Participants	Depends	Start	Due
MS3	At least 1 IBMC-based polymer shows preliminary suitable behaviour for one of the applications	1	-	-	-	27

2.7 WP6: Bifunctional catheters application proof of principle

TABLE 2.7: WBS FOR WP6						
Participant number	1	3				
Short name of participant	TECNALIA	CIKAUTXO				

Participant number	T	3	
Short name of participant	TECNALIA	CIKAUTXO	

ID	Description	Lead	Participants	Depends	Start	Due
WP6	Bifunctional catheters application proof-of-principle	3	1	-	13	36
T6.1	Synthesis of bio-functionalized thermoplastic IBMC-based NIPUs.	1	3	T3.4, T6.2	13	24
T6.2	Processing of bio-functional IBMC-based NIPU into a catheter	3	1	T6.1, T6.3	24	36
T6.3	Assessment of Biocompatibility and biofunctionality of the final prototype	1	3	T6.2	24	36

						Partn	ler nº				
~	Project	1	2	3	4	5	6	7	8	9	т
(Md)	T6.1	15	0	3	0	0	0	0	0	0	18
ort (T6.2	10	0	9	0	0	0	0	0	0	19
Effort	T6.3	15	0	5	0	0	0	0	0	0	20
ned	Total	40	0	17	0	0	0	0	0	0	57
Planned											
<u> </u>	RP1	1	2	3	4	5	6	7	8	9	т





	ſ									
T6.1	7.5	0	1.5	0	0	0	0	0	0	9
T6.2	0	0	0	0	0	0	0	0	0	0
T6.3	0	0	0	0	0	0	0	0	0	0
Total	7.5	0	1.5	0	0	0	0	0	0	9
RP2	1	2	3	4	5	6	7	8	9	т
T6.1	7.5	0	1.5	0	0	0	0	0	0	9
T6.2	10	0	9	0	0	0	0	0	0	19
T6.3	15	0	5	0	0	0	0	0	0	20
Total	32.5	0	15.5	0	0	0	0	0	0	48

ID	Description	Lead	Participants	Depends	Start	Due
D6.1	Synthesis of biofunctionalized	1	2, 9	T6.1	-	24
	thermoplastic IBMCbased NIPUs.					
D6.2	Processing of biofunctional	9	2	T6.2	-	36
	IBMC-based NIPU into a catheter					
D6.3	Biocompatibility and bio	1	2	T6.3	-	36
	functionality of the final prototype					

ID	Description	Lead	Participants	Depends	Start	Due
MS3	At least 1 IBMC-based polymer shows preliminary suitable behaviour for one of the applications	1	-	-	-	27

2.8 WP7: LCA, REACH and cost analysis

				2.0	5100				
Participant number	1	2	3	4	5	6	7	8	9
Short name of participant	TECNALIA	JOWAT	CIKAUTXO	B4P	AEP	VERTECH	EXERGY	GAIKER	LEITAT

TABLE 2.8: WBS FOR WP7

ID	Description	Lead	Participants	Depends	Start	Due
WP7	LCA, REACH and cost analysis	6	1, 2, 3, 4, 5, 7, 8, 9	-	6	36
T7.1	Technical evaluation of VIPRISCAR concepts	7	1, 4	T3.5	6	30
T7.2	Economic validation: Life cycle cost analysis (LCC) and economic feasibility	6	1, 2, 3, 4, 5, 7, 8, 9	T3.5, T4.3, T5.3, T6.2	6	36
T7.3	Environmental feasibility study including life cycle assessment (LCA)	6	1, 2, 3, 4, 5, 7, 8, 9	T3.5, T4.3, T5.3, T6.2	6	34
T7.4	Health and safety study (HSS)	1	6	T3.5, T4.3, T5.3, T6.2	6	32





T7.5	Definition of European and level level	c	1 2 2 4 5 7 8 0	T7 4	C	36
17.5	Definition of European and local legal	0	1, 2, 3, 4, 5, 7, 8, 9	17.4	0	30
	and non-legal limitations, barriers and					
	standards					

						Partn	er nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T7.1	1	0	0		0	0	8	0	0	9
	T7.2	2	0.25	0.25	0.25	0.25	9	0.5	1	1	14.5
	T7.3	2	0.25	0.25	0.25	0.25	9	0.25	1	1	14.25
	T7.4	7	0	0	0	0	5	0	0	0	12
	T7.5	1	0.5	0.5	0.5	0.5	9	0.25	1	1	14.25
	Total	13	1	1	1	1	32	9	3	3	64
=	RP1	1	2	3	4	5	6	7	8	9	Т
Planned Effort (PM)	T7.1	0.57	0	0	0	0	0	1.20	0	0	1.77
	T7.2	1.14	0.14	0.14	0.14	0.14	5.14	0.10	0.57	0.57	8.10
A Eff	T7.3	1.14	0.14	0.14	0.14	0.14	5.14	0.10	0.57	0.57	8.10
nec	T7.4	4	0	0	0	0	2.86	0	0	0	6.86
Plar	T7.5	0.57	0.29	0.29	0.29	0.29	5.14	0.10	0.57	0.57	8.10
	Total	7.43	0.57	0.57	0.57	0.57	18.29	1.50	1.71	1.71	32.93
	RP2	1	2	3	4	5	6	7	8	9	т
	T7.1	0.43	0	0	0	0	0	6.80	0	0	7.23
	T7.2	0.86	0.11	0.11	0.11	0.11	3.86	0.40	0.43	0.43	6.40
	T7.3	0.86	0.11	0.11	0.11	0.11	3.86	0.15	0.43	0.43	6.15
	T7.4	3	0	0	0	0	2.14	0	0	0	5.14
	T7.5	0.43	0.21	0.21	0.21	0.21	3.86	0.15	0.43	0.43	6.15
	Total	5.57	0.43	0.43	0.43	0.43	13.71	7.50	1.29	1.29	31.07

ID	Description	Lead	Participants	Depends	Start	Due
D7.1	Report on technical feasibility study	7	1, 4	T7.1	-	20
	for process technologies (I)					
D7.2	Report on technical feasibility study	7	1, 4	T7.1	-	30
	for process technologies (II)					
D7.3	Economic feasibility report including	6	1, 2, 3, 4, 5, 7, 8, 9	T7.2	-	24
	CAPEX and OPEX quantification (I)					
D7.4	Economic feasibility report including	6	1, 2, 3, 4, 5, 7, 8, 9	T7.2	-	36
	CAPEX and OPEX quantification (II)					
D7.5	Environmental validation including a	6	1, 2, 3, 4, 5, 7, 8, 9	T7.3	-	22
	Life Cycle Assessment (I)					
D7.6	Environmental validation including a	6	1, 2, 3, 4, 5, 7, 8, 9	T7.3	-	34
	Life Cycle Assessment (II)					
D7.7	Health and safety study	1	6	T7.4	-	32
D7.8	European and local legal and non-legal	6	1, 2, 3, 4, 5, 7, 8, 9	T7.5	-	12
	limitations, barriers and standards for					





	VIPRISCAR products (I)					
D7.9	European and local legal and non-legal limitations, barriers and standards for VIPRISCAR products (II)	6	1, 2, 3, 4, 5, 7, 8, 9	T7.5	-	24
D7.10	European and local legal and non-legal limitations, barriers and standards for VIPRISCAR products (III)	6	1, 2, 3, 4, 5, 7, 8, 9	T7.5	-	36
D7.11	List of Key Performance Indicators	6	1, 2, 3, 4, 5, 7, 8, 9	T7.5	-	25

2.9 WP8: Exploitation, Dissemination and Communication

		-	TABLE	2.9: WE	BS FOR	WP8			
Participant number	1	2	3	4	5	6	7	8	9
Short name of participant	TECNALIA	JOWAT	CIKAUTXO	B4P	AEP	VERTECH	EXERGY	GAIKER	LEITAT

ID	Description	Lead	Participants	Depends	Start	Due
WP8	Exploitation, Dissemination and	6	1, 2, 3, 4, 5, 7, 8, 9	-	1	36
	Communication					
T8.1	Market intelligence and competitive	6	2, 3, 4, 5	-	1	12
	analysis					
T8.2	Business models and financial impacts	6	2, 3, 4, 5	T7.2	12	36
T8.3	Exploitation Plan	6	1, 2, 3, 4, 5, 7, 8, 9	-	1	36
T8.4	IPR and Exploitation Risk Management	6	1, 2, 3, 4, 5, 7, 8, 9	-	1	36
T8.5	Development of the Project	1	2, 3, 4, 5, 6, 7, 8, 9	-	1	36
	communication and dissemination					
	strategy					

						Partn	er nº				
	Project	1	2	3	4	5	6	7	8	9	т
	T8.1	0	0.3	0.3	0.3	0.3	5	0	0	0	6.2
~	T8.2	0	0.3	0.3	0.3	0.3	5	0	0	0	6.2
Effort (PM)	T8.3	2	0.2	0.2	0.2	0.2	9	0.5	0.5	0.5	13.3
ort (T8.4	2	0.1	0.1	0.1	0.1	8	1.25	0.5	0.5	12.65
	T8.5	10	0.1	0.1	0.1	0.1	1	1.25	2	2	16.65
ned	Total	14	1	1	1	1	28	3	3	3	55
Planned											
_	RP1	1	2	3	4	5	6	7	8	9	Т
	T8.1	0	0.3	0.3	0.3	0.3	5	0	0	0	6.2
	T8.2	0	0.17	0.17	0.17	0.17	2.86	0	0	0	3.54



Bio-based Industries Consortium

T8.3	1	0.1	0.1	0.1	0.1	4.5	0.25	0.25	0.25	6.65
T8.4	1	0.05	0.05	0.05	0.05	4	0.25	0.25	0.25	5.95
T8.5	5	0.05	0.05	0.05	0.05	0.5	0.25	1	1	7.95
Total	7	0.67	0.67	0.67	0.67	16.86	0.75	1.5	1.5	30.29
RP2	1	2	3	4	5	6	7	8	9	т
T8.1	0	0	0	0	0	0	0	0	0	0
T8.2	0	0.13	0.13	0.13	0.13	2.14	0	0	0	2.66
T8.3	1	0.1	0.1	0.1	0.1	4.5	0.25	0.25	0.25	6.65
Т8.4	1	0.05	0.05	0.05	0.05	4	1	0.25	0.25	6.7
T8.5	5	0.05	0.05	0.05	0.05	0.5	1	1	1	8.7
Total	7	0.33	0.33	0.33	0.33	11.14	2.25	1.5	1.5	24.71

ID	Description	Lead	Participants	Depends	Start	Due
D8.1	Market analysis for VIPRISCAR innovations	6	2, 3, 4, 5	T8.1	-	12
D8.2	Business plan (I)	6	2, 3, 4, 5	T8.1, T8.2	-	24
D8.3	Business plan (II)	6	2, 3, 4, 5	T8.1, T8.2	-	36
D8.4	Data management plan (I)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3	-	6
D8.5	Data management plan (II)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3	-	24
D8.6	Data management plan (III)	6	1, 2, 3, 4, 5, 7, 8, 9	Т8.3	-	36
D8.7	Exploitation plan (I)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3, T8.4	-	6
D8.8	Exploitation plan (II)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3, T8.4	-	12
D8.9	Exploitation plan (III)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3, T8.4	-	24
D8.10	Exploitation plan (IV)	6	1, 2, 3, 4, 5, 7, 8, 9	T8.3, T8.4	-	36
D8.11	Dissemination and communication plan (I)	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	-	6
D8.12	Dissemination and communication plan (II)	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	-	12
D8.13	Dissemination and communication plan (III)	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	-	24
D8.14	Dissemination and communication plan (IV)	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	-	36
D8.15	Project public website	1	2, 3, 4, 5, 6, 7, 8, 9	T8.5	-	4

2.10 WP9: Ethics Requirement

TABLE 2.10: WBS FOR WP9

Participant number	1	2	3	4	5	6	7	8	9
Short name of participant	TECNALIA	TAWOL	CIKAUTXO	B4P	AEP	VERTECH	EXERGY	GAIKER	LEITAT

ID	Description	Lead	Participants	Depends	Start	Due
D9.1	A - Requirement No. 1	1	2, 3, 4, 5, 6, 7, 8, 9	-	-	6
D9.2	EPQ - Requirement No. 2	1	2, 3, 4, 5, 6, 7, 8, 9	-	-	1





3. GRAPHICAL PRESENTATION OF TASKS INTERDEPENDENCIES

The Figure 3.1 graphically summarises the inter-relationships among the different project tasks presented in the sections before.

	T1.1. Project coordination and quality assurance	T1.2. Communication, reporting and monitoring		
			T8.5. Developn Project commun dissemination	nication and
T2.1. Reaction improvement T2.2. Separation and purification procedure T2.2. Separation	2.3. Pre-up- scaling T3.1. Intermediate scaling-up		T8.1. Market intelligence and competitive analysi	
T2.4 Process design and integration	T3.2. Pilot plant design		T8.4. IPR and Risk Mana	Exploitation
T2.5. Process simulation and preliminary up-scaling	T3.3. Pilot plant starting		Nisk Wahl	Beneur
T3.5. Plant up-scaling simulation to industrial scale	T3.4. Pilot plant operation	T4.1. Waterborne polyurethane dispersions (PUDs) for coatings	T5.1. Adhesives based on IBMC and commercial polyester/polyether polyols	T6.1. Synthesis of bio- functionalized thermoplast IBMC-based NIPUs.
		T4.2. IBMC based NIPUs for coatings	T5.2. NIPUs-based adhesives	T6.2. Processing of bio- functional IBMC-based NIPU into a catheter
7.1. Technical evaluation of VIPRISCAR concepts		T4.3. Coating formulation and testing of properties	T5.3. Adhesives formulation and testing of properties	T6.3. Assessment of Biocompatibility and biofunctionality of the final prototype
and financial impacts cycle		T7.3. Environmental feasibility study including ife cycle assessment (LCA)	safety study (HSS)	17.5. Definition of European am local legal and non-legal mitations, barriers and standard

FIGURE 3.1: TASK INTERDEPENDENCIES





4. SCHEDULE MANAGEMENT

The project schedule will be managed through success criteria, milestones and periodic control mechanisms.

4.1 PROJECT SUCCESS CRITERIA

A set of success criteria have been defined per deliverable and Work Package as it is shown in Table

WP	Success indicator	Deliverable
1	First version of the Quality Assurance Plan documented	D1.1
1	The Quality Assurance Plan revised	D1.2
1	The Quality Assurance Plan revised	D1.3
1	Definitive version of the Quality Assurance Plan	D1.4
1	First version of the Project Management Plan available	D1.5
1	Project Management Plan updated	D1.6
1	Project Management Plan updated	D1.7
1	Definitive version of the Project Management Plan	D1.8
2	Intermediate results of the IBMC process development documented	D2.1
2	IBMC process development. Lab Technology Manual available	D2.2
2	Process simulation and preliminary up-scaling completed	D2.3
3	Report confirming validation and giving adaptation/investment strategy for the IBMC pilot process	D3.1
3	Protocol for IBMC process that has proven to result in the first 100-kg	D3.2
3	Plant up-scaling simulation completed	D3.3
4	Documented preparation of polyurethane dispersions (PUDs) with IBMC functional oligomers for coating formulation.	D4.1
4	IBMC derived NIPUs with amino terminal groups available	D4.2
4	IBMC based coatings form POUDs and NIPUS available	D4.3
5	Results documented.	D5.1

TABLE 4.1: PROJECT SUCCESS CRITERIA





S S0 g of polycarbonate polyols have been produced and characterized. Report is available. D5.2 S First NIPUs are available. D5.3 S 2 kg raw materials for adhesive formulation has been delivered to JOWAT. Report is available. D5.4 S Final formulation of NIPUs are available. D5.5 S Adhesive formulations are developed and characterized. D5.6 6 IBMC-based biofunctionalized NIPU synthetized D6.1 6 A proof if principle catheter of IBCM-based NIPU processed D6.2 6 The biocompatibility and bifunctionality of the final prototype evaluated. D7.1 7 Preliminary technical feasibility study completed D7.2 7 Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysis D7.4 7 Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification) D7.5 7 Final environmental assessment, including LCA results D7.6			
5 2 kg raw materials for adhesive formulation has been delivered to JOWAT. Report is available. D5.4 5 Final formulation of NIPUs are available. D5.5 5 Adhesive formulations are developed and characterized. D5.6 6 IBMC-based biofunctionalized NIPU synthetized D6.1 6 A proof if principle catheter of IBCM-based NIPU processed D6.2 6 The biocompatibility and bifunctionality of the final prototype evaluated. D7.1 7 Preliminary technical feasibility study completed D7.2 7 Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysis D7.4 7 Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification) D7.4 7 Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysis D7.6 7 Final environmental assessment, including LCA results D7.6 7 First screening of European and local legal and non-legal limitations, barriers and standards identification D7.9 7 Lipate of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR products D7.10 7 Final analysis of the European and local legal and n	5		D5.2
JOWAT. Report is available. D5.5 5 Final formulation of NIPUs are available. D5.5 5 Adhesive formulations are developed and characterized. D5.6 6 IBMC-based biofunctionalized NIPU synthetized D6.1 6 A proof if principle catheter of IBCM-based NIPU processed D6.2 6 The biocompatibility and bifunctionality of the final prototype evaluated. D7.1 7 Preliminary technical feasibility study completed D7.1 7 Technical feasibility study completed D7.2 7 Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysis D7.4 7 Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification) D7.4 7 Final environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysis D7.6 7 Final environmental assessment, including LCA results D7.6 7 Final environmental assessment, including LCA results D7.7 7 First screening of European and local legal and non-legal limitations, barriers and standards identification D7.9 7 Vupdate of the European and local legal and non-legal limitations, barriers and standards,	5	First NIPUs are available.	D5.3
5Adhesive formulations are developed and characterized.D5.66IBMC-based biofunctionalized NIPU synthetizedD6.16A proof if principle catheter of IBCM-based NIPU processedD6.26The biocompatibility and bifunctionality of the final prototype evaluated.D6.37Preliminary technical feasibility study completedD7.17Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.67Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	5	-	D5.4
6IBMC-based biofunctionalized NIPU synthetizedD6.16A proof if principle catheter of IBCM-based NIPU processedD6.26The biocompatibility and bifunctionality of the final prototype evaluated.D6.37Preliminary technical feasibility study completedD7.17Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	5	Final formulation of NIPUs are available.	D5.5
6A proof if principle catheter of IBCM-based NIPU processedD6.26The biocompatibility and bifunctionality of the final prototype evaluated.D6.37Preliminary technical feasibility study completedD7.17Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental study, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	5	Adhesive formulations are developed and characterized.	D5.6
6The biocompatibility and bifunctionality of the final prototype evaluated.D6.37Preliminary technical feasibility study completedD7.17Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental study, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	6	IBMC-based biofunctionalized NIPU synthetized	D6.1
evaluated.7Preliminary technical feasibility study completedD7.17Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental study, including LCA resultsD7.67Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	6	A proof if principle catheter of IBCM-based NIPU processed	D6.2
7Technical feasibility study completedD7.27Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.97Vipdate of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.118Market analysis availableD8.1	6		D6.3
7Preliminary economic feasibility study, including the Life Cycle Costing (LCC) methodology definition and screening analysisD7.37Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.67Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.117Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7	Preliminary technical feasibility study completed	D7.1
(LCC) methodology definition and screening analysis7Final economic feasibility analysis, including LCC results (CAPEX and OPEX quantification)D7.47Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.108Market analysis availableD8.1	7	Technical feasibility study completed	D7.2
OPEX quantification)D7.57Preliminary environmental study, including the Life Cycle Assessment (LCA) methodology and screening analysisD7.57Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7		D7.3
(LCA) methodology and screening analysis7Final environmental assessment, including LCA resultsD7.67The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7		D7.4
7The health and safety study finishedD7.77First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.107Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7		D7.5
7First screening of European and local legal and non-legal limitations, barriers and standards identificationD7.87Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7	Final environmental assessment, including LCA results	D7.6
barriers and standards identificationD7.97Update of the European and local legal and non-legal limitations, barriers and standards, validation from partners involvedD7.97Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7	The health and safety study finished	D7.7
barriers and standards, validation from partners involved7Final analysis of the European and local legal and non-legal limitations, barriers and standards for VIPRISCAR productsD7.107Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7		D7.8
barriers and standards for VIPRISCAR products7Full list of Key Performance Indicators corresponding to the WP7 (technical, economic, environmental and health & safety aspects)D7.118Market analysis availableD8.1	7		D7.9
(technical, economic, environmental and health & safety aspects)8Market analysis availableD8.1	7		D7.10
	7		D7.11
8 First version of the Business plan of commercial KERs documented D8.2	8	Market analysis available	D8.1
	8	First version of the Business plan of commercial KERs documented	D8.2





8	Final version of the Business plan of commercial KERs available	D8.3		
8	First version of the Data management plan documented	D8.4		
8	Second version of the Data management plan updated	D8.5		
8	Final version of the Data management plan available	D8.6		
8	First version of the exploitation plan documented	D8.7		
8	Second version of the exploitation plan updated	D8.8		
8	Third version of the exploitation plan updatedD8.9			
8	Final version of the exploitation plan availableD8.10			
8	Full version of the dissemination and communication plan available	D8.11		
8	Assessment of the dissemination and communication activities deployed in the first year	D8.12		
8	Assessment of the dissemination and communication activities deployed in the second year	D8.13		
8	Assessment of the dissemination and communication activities deployed in the third year	D8.14		
8	Website operational with initial contents	D8.15		
9	Authorisations for the realization of experiments obtained	D9.1		
9	Authorisations for relevant facilities obtained	D9.2		

4.2 MILESTONES

The Table 4.2 list the significant milestones in the project, their timing and the means of verification. TECNALIA will be responsible to track progress to milestone achievement.

Milestone	Milestone name	Related WP(s)	Due date	Means of verification
MS1	Production of 1 kg of IBMC	2	12	1 kg of IBMC obtained at lab scale
MS2	100 kg of IBMC produces + Positive preliminary technical and economic study + Positive	3, 7	24	At least 100 kg of IBMC produced at PP scale + Reports







	preliminary environmental feasibility and health study			
MS3	At least 1 IBMC-based polymer shows preliminary suitable behaviour for one of the applications	4, 5, 6	27	Report

4.3 CONTROL MECHANISMS

The actual schedule performance will be compared to planned performance in order to implement corrective action when actual performance deviates from planned or required performance.

The Project Management Plan will be updated three times during the project execution (at Months 12, 24 and 36).

Furthermore, Work Package and Tasks Leaders will be responsible of reporting on their activities at every Project Steering Committee meeting (every 6 months) in order to allow project progress to be tracked seamlessly.

The actual Gantt Chart will then reflect progress achieved and agreement of the revised schedule, if necessary.



Biobased	BIO-BASED INDUSTRIES
I Industries Consortium	**** * * ***

					YEA	K I							IL	AR 2			
VIPRISCAR	Jun	Jul	Ago Se	ep Oc	t Nov	Dic F	En Fel	b Mar	Abr May	Jun J	ul Ago s	Sep O	ct Nov	Dic F	En Fe	b Mar	Abr
WP1 - Management and Scientific coordination																	
T1.1 Project coordination and quality assurance		1	D1.1						D1.1								
T1.2 Communication, reporting and monitoring		1	D1.2						D1.2								
WP2 - Process development and validation of IBMC at lab scale																	
T2.1 Reaction improvement					D2.1												
T2.2 Separation and purification procedure	i i																
T2.3 Pre-uspcaling	Í								D2.2								
T2.4 Process design and integration																	
T2.5 Process simulation and preliminary up-scaling	Í								D2.3								
WP3 - Validation of the process at pilot scale																	
T3.1 Intermediate scaling-up																	
T3.2 Pilot plant design	Í																
T3.3 Pilot plant starting	ĺ																
T3.4 Pilot plant operation											I	03.1					
T3.5 Plant up-scaling simulation to industrial scale																	
WP4 - Coatings application proof of principle																_	
T4.1 Waterborne polyurethane dispersions for coatings																	
T4.2 IBMC-based NIPUS for coatings	Í																
T4.3 Coatings formulation and testing of properties																	
WP5 - Adhesives application proof of principle																	
T5.1 Adhesives based on IBMC and commercial polyester/polyether polyols														D	5.2		
T5.2 NIPUS-based adhesives	Í										D5.1			D	5.3		
T5.3 Adhesives formulation and testing of properties																	
WP6 - Biomedical application proof of principle					· · ·												
T6.1 Synthesis of bio-functionalized thermoplastic IBMC-based NIPUs																	
T6.2 Processing of bio-functional IBMC-based NIPU into a catheter																	
T6.3 Assessment of biocompatibility and biofunctionality of the final prototype																	
WP7 - LCA Reach and cost analysis																	
T7.1 Technical evaluation of VIPRISCAR concepts														D	7.1		
T7.2 Economic validation: Life cycle cost analysis and economic feasibility	Í																
T7.3 Environmental feasibility study including Life Cycle Assessment	Í															D7.3	5
T7.4 Health and safety study	Í																
T7.5 Definition of European and local legal and non-legal limitations, barriers and standards									D7.5								
WP8 - Exploitation, Dissemination and Communication																	
T8.1 Market intelligence and competitive analysis									D8.1								
T8.2 Business models and financial impacts																	
T8.3 Exploitation Plan					D8.3												
T8.4 IPR and Exploitation Risk Management					D8.4				D8.4								
T8.5 Development of the Project communication and dissemination strategy			DS		D8.5				D8.5								

VEAD

MT1

MILESTONES

ANNEX I: VIPRISCAR GANTT CHART

Jun Jul Ago Sep Oct Nov Dic En Feb Mar Abr May

D4.1 D4.2

D5.4 D5.5

MT 3

MT2

D7.1

D1. D1.2

D4

D6. D6.

D7.

D7.

D8.

D8.3 D8.4

D8.

D7.3

D7.4





CONTACT DETAILS

Soraya Prieto Fernández Project Manager, TECNALIA www.vipriscar.eu



This project has received funding from the Bio Based Industries Joint Undertaking (JU) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 790440. The JU receives support from the European Union's Horizon 2020 research and innovation programme and the Bio Based Industries Consortium.